N⁴-(m-tolyl)-1,3,5-triazaspiro[5.5]undeca-1,3-diene-2,4-diamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N⁴-(m-tolyl)-1,3,5-triazaspiro[5.5]undeca-1,3-diene-2,4-diamine
• 英文别名: N~4~-(3-methylphenyl)-1,3,5-triazaspiro[5.5]undeca-1,3-diene-2,4-diamine；4-N-(3-methylphenyl)-1,3,5-triazaspiro[5.5]undeca-1,4-diene-2,4-diamine
• 化学式: C₁₅H₂₁N₅
• 分子量: 271.365
• InChiKey: XNYMRFXNQINRFX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  74.8
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  5-(m-tolyl)-1,3,5-triazaspiro[5.5]undeca-1,3-diene-2,4-diamine 以 吡啶 、 乙醇 为溶剂， 以40%的产率得到N⁴-(m-tolyl)-1,3,5-triazaspiro[5.5]undeca-1,3-diene-2,4-diamine
  参考文献：
  名称：

  Exploring Halogen Bonds in 5-Hydroxytryptamine 2B Receptor–Ligand Interactions

  摘要：

  Here, we predicted the potential halogen bonding interaction between compound 2 and the 5-hydroxytryptamine 2B (5-HT2B) receptor and systematically assessed this interaction via structure activity relationship analysis and molecular dynamics simulations. A physics-based computational protocol was then developed to further explore the opportunity of "designing in" halogen bonding interactions in structure-based ligand design for the 5-HT2B receptor, which not only facilitated the identification of previously uncharacterized halogen bonds in known 5-HT2B ligands but also enabled the rational design of halogen bonding interactions for the optimization of 5-HT2B ligands. As a proof-of-concept, a series of halogen-substituted analogues of doxepin synthesized and evaluated, which showed improved in vitro and in vivo potency.

  DOI：

  10.1021/acsmedchemlett.8b00300

文献信息

• 5-HT2B Antagonists
  申请人：National Institute of Biological Sciences, Beijing

  公开号：US20170029385A1

  公开（公告）日：2017-02-02

  The invention provides novel compounds and compositions comprising a 5-HT 2B antagonist of formula I: and related methods for treating a person having a disorder characterized by undesirable 5-HT 2B receptor signaling, such as migraine, irritable bowel syndrome (IBS), pulmonary arterial hypertension (PAH), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (GI) tract disorders.
• US9751845B2
  申请人：——

  公开号：US9751845B2

  公开（公告）日：2017-09-05
• US9845298B1
  申请人：——

  公开号：US9845298B1

  公开（公告）日：2017-12-19